MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

    L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

    Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…
  • 2025 International Congress

    Updated Meta-analysis Assessing GLP-1 Agonists for Parkinson’s Disease

    M. Messak, A. Abdelmageed, Y. Khattab (Helwan, Egypt)

    Objective: Evaluate the efficacy and safety of Glucagon-like peptide-1 (GLP-1) agonists on Parkinson’s disease (PD). Background: The idea of ​​repositioning drugs used to treat PD…
  • 2025 International Congress

    Organoid-Based AI Clinical Trial Platform for Phase 0 Studies in Parkinson’s Disease

    M. Choi, D. Kim (Daejoen, Republic of Korea)

    Objective: we developed an organoid-based AI-driven platform to classify patient specific molecular subtypes and predict drug efficacy through an AI-powered validation pipeline. Patient-derived induced pluripotent…
  • 2025 International Congress

    Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics

    J. Suh, R. Maciuca, E. Macklin, S. Davis, J. Kluss, N. Xia, H. Yazd, M. Schwarzschild, S. Huntwork-Rodriguez (South San Francisco, USA)

    Objective: Define lipid signatures in sporadic, LRRK2, and GBA1 PD and pre-manifest carriers and assess medication impacts. Background: Lysosomal dysfunction contributes to PD, particularly in…
  • 2025 International Congress

    Biomarker Panels for Parkinson’s Disease using Multi-Omics Approach: Recent Developments and Future Directions

    PRA. Sharma, RK. Dhamija (Delhi, India)

    Objective: The main objective is to identify potential biomarker panels that may represent disease onset, progression, and risk factors for Parkinson's disease (PD). Background: PD…
  • 2025 International Congress

    Sex Differences in α-Synuclein Seed Amplification Assay Parameters and Longitudinal Clinical Subtypes of Parkinson’s Disease

    SM. Fereshtehnejad, J. Lökk (TORONTO, Canada)

    Objective: To investigate differences in baseline α-synuclein seed amplification assay (SAA) metrics and longitudinal clinical subtypes of Parkinson’s disease (PD) between the two biological sexes.…
  • 2025 International Congress

    AntiSaccadeNet: A Deep Learning Framework for Differentiating Parkinsonian Disorders through Antisaccade Time Series Classification

    S. Patel, C. Antoniades, J. Fitzgerald, O. Bredemeyer (Oxford, United Kingdom)

    Objective: To develop and evaluate a deep learning architecture (AntiSaccadeNet) that utilizes continuous antisaccade eye movement time-series data to differentiate between Parkinson's disease (PD) and…
  • 2025 International Congress

    Sleep-wake modulation of subthalamic activity in patients with Parkinson’s disease and conventional or adaptive deep brain stimulation

    L. Caffi, R. Habib, S. Bonvegna, M. Pilleri, G. Pezzoli, C. Palmisano, A. Mazzoni, IU. Isaias (Milan, Italy)

    Objective: To describe the activity of the subthalamic nucleus (STN) during wake and sleep in patients with Parkinson’s disease (PD) with conventional (cDBS) or adaptive…
  • 2025 International Congress

    Enhancing Step Detection in Real-World Gait

    A. Ena, C. Mazzà, E. Bartholomé, C. Bernasconi, S. Belachew, ó. Reyes (Basel, Switzerland)

    Objective: To enhance accuracy and applicability of algorithms for step detection obtained from free-living gait accelerometer data in individuals with Parkinson’s Disease (PD). Background: When…
  • 2025 International Congress

    Role of APOE Polymorphism and CSF Markers of AD Co-Pathology in the Cognitive Trajectories of Sporadic and Genetic Parkinson’s Disease: A Longitudinal Cohort Study

    R. Botta, J. Locascio, R. Ye, A. Goodheart, S. Gomperts (Boston, USA)

    Objective: To evaluate if APOE genotype and CSF biomarkers of AD co-pathology are associated with distinct rates of cognitive decline in PD subtypes. Background: Cognitive…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley